Switzerland-based HAYA Therapeutics, a biotech developing precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, has raised $65 million in a Series A funding round.
The financing will accelerate the clinical development of HAYA’s lead long non-coding RNA (lncRNA) targeting candidate, HTX-001, in heart failure, and the continued expansion of its RNA-guided regulatory genome pipeline development engine.
Management has said that the support emphasizes investor confidence in HAYA’s ground-breaking science and positions the company to deliver on its mission of bringing disease-modifying, precision medicines faster and more efficiently to patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze